- 大部份公司都有淡旺季, 所以通常是看年增率
- 如果是成長期(在炒新的成長動能)的公司或景氣從谷底翻揚, 就可以觀察月增率
- 漲很多的股票要留意營收年增率或月增率大幅減少, 又或者是合約負債已經開始減少
- 留意短期平均營收向上或向下穿越長期平均營收
- 觀察累計營收年增率的累計增加或虧損收斂
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/10 | 3.81 | 4.33 | -5.34 | 37.61 | 5.91 | 10.84 | N/A | - | ||
| 2024/9 | 3.65 | 8.02 | -5.19 | 33.8 | 7.34 | 10.31 | 1.83 | - | ||
| 2024/8 | 3.38 | 3.21 | -15.77 | 30.14 | 9.09 | 11.03 | 1.71 | - | ||
| 2024/7 | 3.28 | -25.13 | -4.38 | 26.76 | 13.32 | 12.2 | 1.54 | - | ||
| 2024/6 | 4.38 | -3.73 | -1.65 | 23.49 | 16.33 | 12.15 | 1.47 | - | ||
| 2024/5 | 4.55 | 40.93 | 37.77 | 19.11 | 21.41 | 13.4 | 1.33 | - | ||
| 2024/4 | 3.22 | -42.75 | 3.3 | 14.57 | 17.07 | 11.32 | 1.58 | - | ||
| 2024/3 | 5.63 | 129.29 | 46.06 | 11.34 | 21.68 | 11.34 | 1.49 | 本月營收增加主係合併子公司台新藥認列Eyenovia授權金 | ||
| 2024/2 | 2.46 | -24.42 | -11.3 | 5.71 | 4.47 | 10.65 | 1.59 | - | ||
| 2024/1 | 3.25 | -34.24 | 20.7 | 3.25 | 20.7 | 11.35 | 1.49 | - | ||
| 2023/12 | 4.94 | 56.76 | 32.4 | 43.6 | 15.79 | 12.12 | 1.32 | - | ||
| 2023/11 | 3.15 | -21.66 | -7.72 | 38.66 | 13.97 | 11.03 | 1.45 | - | ||
| 2023/10 | 4.03 | 4.5 | 13.99 | 35.51 | 16.4 | 11.89 | 1.34 | - | ||
| 2023/9 | 3.85 | -4.02 | -4.83 | 31.48 | 16.71 | 11.29 | 1.47 | - | ||
| 2023/8 | 4.01 | 17.15 | 43.84 | 27.63 | 20.52 | 11.89 | 1.4 | - | ||
| 2023/7 | 3.43 | -22.98 | 0.71 | 23.62 | 17.29 | 11.17 | 1.48 | - | ||
| 2023/6 | 4.45 | 34.85 | 43.34 | 20.19 | 20.66 | 10.87 | 1.6 | - | ||
| 2023/5 | 3.3 | 5.67 | 37.74 | 15.74 | 15.49 | 10.28 | 1.69 | - | ||
| 2023/4 | 3.12 | -19.05 | 8.24 | 12.44 | 10.75 | 9.75 | 1.78 | - | ||
| 2023/3 | 3.86 | 39.23 | 12.66 | 9.32 | 11.62 | 9.32 | 1.73 | - | ||
| 2023/2 | 2.77 | 2.84 | 34.08 | 5.46 | 10.89 | 9.2 | 1.75 | - | ||
| 2023/1 | 2.69 | -27.86 | -5.84 | 2.69 | -5.84 | 9.84 | 1.64 | - | ||
| 2022/12 | 3.73 | 9.24 | 16.2 | 37.66 | 19.82 | 10.68 | 1.5 | - | ||
| 2022/11 | 3.42 | -3.22 | 9.91 | 33.92 | 20.24 | 11.0 | 1.46 | - | ||
| 2022/10 | 3.53 | -12.75 | 37.48 | 30.5 | 21.52 | 10.37 | 1.54 | - | ||
| 2022/9 | 4.05 | 45.06 | 44.8 | 26.97 | 19.7 | 10.24 | 1.52 | - | ||
| 2022/8 | 2.79 | -17.96 | 31.03 | 22.92 | 16.14 | 9.3 | 1.68 | - | ||
| 2022/7 | 3.4 | 9.61 | 77.51 | 20.13 | 14.34 | 8.9 | 1.75 | 本月較同期增加主係膽固醇磷酸鹽結合劑歐洲客戶訂單增加及呼吸系統用藥接獲來自大陸客戶訂單所致。 | ||
| 2022/6 | 3.1 | 29.58 | 8.33 | 16.73 | 6.62 | 8.38 | 1.97 | - | ||
| 2022/5 | 2.39 | -16.95 | -4.78 | 13.63 | 6.24 | 8.7 | 1.89 | - | ||
| 2022/4 | 2.88 | -15.75 | -2.2 | 11.23 | 8.93 | 8.37 | 1.97 | - | ||
| 2022/3 | 3.42 | 65.71 | 35.0 | 8.35 | 13.4 | 8.35 | 1.92 | - | ||
| 2022/2 | 2.07 | -27.78 | -15.15 | 4.93 | 2.05 | 8.14 | 1.97 | - | ||
| 2022/1 | 2.86 | -10.97 | 19.57 | 2.86 | 19.57 | 9.18 | 1.74 | - | ||
| 2021/12 | 3.21 | 3.33 | -3.56 | 31.42 | 2.17 | 8.89 | 1.84 | - | ||
| 2021/11 | 3.11 | 21.04 | 49.73 | 28.21 | 2.87 | 8.47 | 1.93 | - | ||
| 2021/10 | 2.57 | -8.11 | -4.7 | 25.1 | -0.96 | 7.49 | 2.19 | - | ||
| 2021/9 | 2.8 | 31.27 | -0.38 | 22.53 | -0.51 | 6.84 | 2.33 | - | ||
| 2021/8 | 2.13 | 11.13 | -27.24 | 19.74 | -0.53 | 6.91 | 2.31 | - | ||
| 2021/7 | 1.92 | -33.1 | -20.62 | 17.61 | 4.07 | 7.3 | 2.19 | - | ||
| 2021/6 | 2.86 | 13.89 | 2.72 | 15.69 | 8.19 | 8.33 | 1.87 | - | ||
| 2021/5 | 2.52 | -14.7 | -3.24 | 12.83 | 9.49 | 8.0 | 1.95 | - | ||
| 2021/4 | 2.95 | 16.29 | 18.48 | 10.31 | 13.12 | 7.92 | 1.97 | - | ||
| 2021/3 | 2.54 | 4.13 | -12.24 | 7.36 | 11.11 | 7.36 | 2.06 | - | ||
| 2021/2 | 2.43 | 1.78 | 25.13 | 4.83 | 29.17 | 8.16 | 1.86 | - | ||
| 2021/1 | 2.39 | -28.2 | 33.56 | 2.39 | 33.56 | 7.8 | 1.94 | - | ||
| 2020/12 | 3.33 | 60.45 | 15.96 | 30.75 | 11.55 | 8.1 | 1.79 | - | ||
| 2020/11 | 2.08 | -22.96 | -3.57 | 27.42 | 11.04 | 7.58 | 1.91 | - | ||
| 2020/10 | 2.7 | -3.94 | 23.08 | 25.35 | 12.44 | 8.43 | 1.72 | - | ||
| 2020/9 | 2.81 | -4.12 | 4.04 | 22.65 | 11.29 | 8.15 | 1.69 | - | ||
| 2020/8 | 2.93 | 21.24 | 18.36 | 19.84 | 12.4 | 8.13 | 1.7 | - | ||
| 2020/7 | 2.41 | -13.43 | -11.43 | 16.92 | 11.43 | 7.8 | 1.77 | - | ||
| 2020/6 | 2.79 | 7.26 | 54.54 | 14.5 | 16.44 | 7.88 | 1.79 | 本月營收增加主因係膽固醇磷酸鹽結合劑產品之印度客戶出貨增加所致。 | ||
| 2020/5 | 2.6 | 4.45 | 31.47 | 11.71 | 9.98 | 7.98 | 1.76 | - | ||
| 2020/4 | 2.49 | -13.87 | 15.29 | 9.12 | 5.08 | 7.32 | 1.92 | - | ||
| 2020/3 | 2.89 | 48.5 | 35.36 | 6.63 | 1.7 | 6.63 | 1.98 | - | ||
| 2020/2 | 1.95 | 8.63 | 3.35 | 3.74 | -14.69 | 6.61 | 1.99 | - | ||
| 2020/1 | 1.79 | -37.65 | -28.29 | 1.79 | -28.29 | 6.82 | 1.93 | - | ||
| 2019/12 | 2.87 | 33.41 | 19.09 | 27.57 | 2.46 | 0.0 | N/A | - | ||
| 2019/11 | 2.15 | -1.66 | -8.37 | 24.69 | 0.82 | 0.0 | N/A | - |
| 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 |
|---|---|---|---|---|---|---|---|---|---|
| 2024/1 | 3.25 | 2023/1 | 2.69 | 2022/1 | 2.86 | 2021/1 | 2.39 | 2020/1 | 1.79 |
| 2024/2 | 2.46 | 2023/2 | 2.77 | 2022/2 | 2.07 | 2021/2 | 2.43 | 2020/2 | 1.95 |
| 2024/3 | 5.63 | 2023/3 | 3.86 | 2022/3 | 3.42 | 2021/3 | 2.54 | 2020/3 | 2.89 |
| 2024/4 | 3.22 | 2023/4 | 3.12 | 2022/4 | 2.88 | 2021/4 | 2.95 | 2020/4 | 2.49 |
| 2024/5 | 4.55 | 2023/5 | 3.3 | 2022/5 | 2.39 | 2021/5 | 2.52 | 2020/5 | 2.6 |
| 2024/6 | 4.38 | 2023/6 | 4.45 | 2022/6 | 3.1 | 2021/6 | 2.86 | 2020/6 | 2.79 |
| 2024/7 | 3.28 | 2023/7 | 3.43 | 2022/7 | 3.4 | 2021/7 | 1.92 | 2020/7 | 2.41 |
| 2024/8 | 3.38 | 2023/8 | 4.01 | 2022/8 | 2.79 | 2021/8 | 2.13 | 2020/8 | 2.93 |
| 2024/9 | 3.65 | 2023/9 | 3.85 | 2022/9 | 4.05 | 2021/9 | 2.8 | 2020/9 | 2.81 |
| 2024/10 | 3.81 | 2023/10 | 4.03 | 2022/10 | 3.53 | 2021/10 | 2.57 | 2020/10 | 2.7 |
| N/A | N/A | 2023/11 | 3.15 | 2022/11 | 3.42 | 2021/11 | 3.11 | 2020/11 | 2.08 |
| N/A | N/A | 2023/12 | 4.94 | 2022/12 | 3.73 | 2021/12 | 3.21 | 2020/12 | 3.33 |
- 每季的合約負債通常會反應在未來半年到一年後的營收
| 合約負債 QoQ YoY | |||
|---|---|---|---|
| 24Q3 (20) | 0.65 | -10.96 | -68.9 |
| 24Q2 (19) | 0.73 | -24.74 | -48.95 |
| 24Q1 (18) | 0.97 | -44.57 | 42.65 |
| 23Q4 (17) | 1.75 | -16.27 | 212.5 |
| 23Q3 (16) | 2.09 | 46.15 | 55.97 |
| 23Q2 (15) | 1.43 | 110.29 | 28.83 |
| 23Q1 (14) | 0.68 | 21.43 | -15.0 |
| 22Q4 (13) | 0.56 | -58.21 | -49.09 |
| 22Q3 (12) | 1.34 | 20.72 | -20.71 |
| 22Q2 (11) | 1.11 | 38.75 | 38.75 |
| 22Q1 (10) | 0.8 | -27.27 | -13.98 |
| 21Q4 (9) | 1.1 | -34.91 | 161.9 |
| 21Q3 (8) | 1.69 | 111.25 | 550.0 |
| 21Q2 (7) | 0.8 | -13.98 | 233.33 |
| 21Q1 (6) | 0.93 | 121.43 | 0 |
| 20Q4 (5) | 0.42 | 61.54 | 0 |
| 20Q3 (4) | 0.26 | 8.33 | 0.0 |
| 20Q2 (3) | 0.24 | 0 | 0.0 |
